Early access
Sign in
Not yet taking people in United StatesNo phase

Adaptive computer program to support older adults with mild cognitive impairment

Tests an adaptive software tool supporting thinking and social contact in mild cognitive impairment.

Key facts

Who runs it
Weill Medical College of Cornell University
Where
Champaign, New York, and Tallahassee, United StatesSee the 3 sites
Trial code
Registry title
Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2
Status
Not yet recruiting
People taking part
120 people, planned
Started
31 Oct 2026
Expected to end
31 May 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Project 2, Phase 2: Intelligent Adaptive System
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for older adults with mild cognitive impairment (MCI), meaning mild memory or thinking problems. They will test a tablet program that gives thinking and social support.

Age
62+ years of age (the record lists a minimum age of 60 Years).
Sex
All sexes can join.
Disease stage
A clinical diagnosis of probable MCI, with own complaints about memory or thinking. Clinical Dementia Rating Global scale of 0.5-2.0. Montreal Cognitive Assessment (MoCA) score of 18-26. No major problems with everyday tasks such as managing money or shopping. No diagnosis of dementia. Geriatric Depression Scale of 4 or below.

Main reasons for not taking part

  • Blindness or sight problems that stop you viewing the tablet. Vision must be 20/60, with or without glasses.
  • Deafness or hearing problems that stop you answering phone questions.
  • A life-limiting or terminal illness.
  • Severe movement problems, such as strong tremors or hand arthritis, that affect speaking or using the main hand.
  • Cognitive impairment with a MOCA score of 25 or lower (as listed in the record). People must also be able to read English at the 6th grade level.

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • 62+ years of age
  • Able to read English at the 6th grade level
  • Have 20/60 vision with or without correction
  • Clinical diagnosis of mild cognitive impairment (MCI)
  • Subjective cognitive complaints
  • Evidence by clinical evaluation
  • Clinical Dementia Rating Global scale of 0.5-2.0
  • Probable MCI
  • Montreal Cognitive Assessment (MoCA) score of 18-26
  • No major Instrumental activities of daily living (IADL) impairments
  • Geriatric Depression Scale of 4 or Below
  • No diagnosis of dementia

Who cannot take part

  • Have a life-limiting/terminal illness
  • Severe motor impairment (e.g., severe tremors or debilitating arthritis in their hands) that impairs ability to speak or use dominant hand
  • Cognitive impairment (MOCA ≤ 25)
  • Blind or have visual impairments that limit their ability to view the technology
  • Deaf or have hearing impairments that limit their ability to answer telephone queries

Where in United States

  • University of Illinois Urbana-ChampaignChampaign, United StatesContact: Wendy Rogers, PhDNot yet recruiting
  • Weill Cornell MedicineNew York, United StatesContact: Chelsie Burchett, MANot yet recruiting
  • Florida State UniversityTallahassee, United StatesContact: Chelsie Burchett, PhDNot yet recruiting

About the trial

What the trial wants to find out

The goal of this Stage 1 (NIH Stage Model) Intervention Development cross-site project is to develop, using a user-centered design approach, and evaluate an innovative intelligent adaptive software package aimed at providing cognitive and social support and engagement to older adults with mild cognitive impairment (MCI). The system will be designed to adapt to the needs and abilities of the user. The investigator's goal is to develop a unique and highly innovative technology tool that can provide adaptive support to aging individuals with MCI, even as cognition might deteriorate further. Speech data collected as part of an embedded reminiscence feature will advance fundamental knowledge of how speech and language production data might serve as an early indicator of cognitive decline.

The 2 groups in the trial

  • Project 2 - Phase 2: Active Intervention GroupTreatment being tested

    Participants will receive a tablet with the adaptive program and be provided with internet service following the baseline assessment. Participants will receive a 3-day training in their home that will include basic tablet/internet training and training on the features of the system. The training will also encompass a module on internet etiquette and security against potential spam and fraud. Participants will be provided with practice tasks in between sessions. Participants will be provided with a "hands-on" performance assessment at the end of the second session and concepts/procedures that are problematic will be reviewed.

    Treatment: Project 2, Phase 2: Intelligent Adaptive System

  • Project 2 - Phase 2: Waitlist ControlExisting treatment, for comparison

    Participants will receive a 3-day training in their home. Participants will also receive a tablet, internet support for 12 months and training. This will include instructions for accessing content pertaining to the research study.

    Treatment: Project 2, Phase 2: Intelligent Adaptive System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Center for Research and Education on Aging and Technology Enhancement - CREATE V
Plain-language title
Adaptive computer program to support older adults with mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
17 August 2026